Author:
Bilson Josh,Oquendo Carolina J.,Read James,Scorletti Eleonora,Afolabi Paul R.,Lord Jenny,Bindels Laure B.,Targher Giovanni,Mahajan Sumeet,Baralle Diana,Calder Philip C.,Byrne Christopher D.,Sethi Jaswinder K.
Funder
EPSRC
National Institute for Health and Care Research
European Society for Clinical Nutrition and Metabolism
National Institute for Health Research Southampton Biomedical Research Centre
Wellcome Trust
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism
Reference61 articles.
1. Non-alcoholic fatty liver disease (NAFLD): a multi-system disease influenced by ageing and sex, and affected by adipose tissue and intestinal function;Bilson;Proc Nutr Soc,2021
2. NAFLD: a multisystem disease;Byrne;J Hepatol,2015
3. Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach;Targher;Lancet Gastroenterol Hepatol,2021
4. Mortality outcomes by fibrosis stage in nonalcoholic fatty liver disease: a systematic review and meta-analysis;Ng;Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc,2022
5. A randomized, controlled trial of the Pan-PPAR agonist Lanifibranor in NASH;Francque;N Engl J Med,2021